Physician profile
John Decerce
NPI 1497724421
$2,291.29
in general payments reported to CMS, 2019-2025
18 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $216 · 2021: $612 · 2022: $610 · 2023: $184 · 2024: $134 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.02 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $501.66 | 2020-2024 | |
| Abbvie INC. | $265.54 | 2021-2025 | Qulipta, Ubrelvy |
| Eisai INC. | $243.35 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $219.85 | 2020-2025 | |
| Upsher-Smith Laboratories LLC | $192.82 | 2020-2022 | |
| Lilly USA, LLC | $140.30 | 2019 | |
| Ucb, INC. | $128.20 | 2019-2025 | Briviact, Nayzilam |
| Pfizer INC. | $126.45 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $125.96 | 2022 | |
| Supernus Pharmaceuticals, INC. | $97.94 | 2019-2021 | |
| Livanova USA, INC. | $48.78 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $47.23 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $42.94 | 2020-2021 | |
| Greenwich Biosciences, INC. | $37.90 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $28.41 | 2019-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.66 | 2019 | |
| Neurelis, INC. | $13.62 | 2021 | |
| Biogen, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Decerce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.